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NPCR and interest of adequacy tests on CAPD. W. Arkouche, E.
Delawari, M. Laville, H. My, and J. Traeger, Aural, Hépital K
Herriot-Service Pr ZECH, Lyon, France. For one year, adequacy tests
have been periodically applied to CAPD patients in our center. Monthly
determinations are as follows:
Residual renal functions (RRF) by analyzing urine volume (VU), urine
urea (UUC) and creatinine (UCC) clearances.
Weekly total urine and peritoneal dialysis (PD) clearances of urea (UC)
and creatinine (CC), normalized to 1.73 m2 of BSA.
Index of dialysis by Teehan (IT).
Weekly Kt/V, where V = 58% of thc body weight (BW).
Protein catabolic rate/24 hr (PCR), calculated as function of the sum of
urine nitrogen + PD nitrogen, non-ureic nitrogen evaluated as 31
mg BW, PD loss of amino acid evaluated as 0.5 g of nitrogen, and the
PD protein loss (P). NPCR = PCRJBW.
24 hr/PD/Reabsorption of glucose (0).
Serum albumin (Mb).
We present preliminary results of 19 patients mean age 67 years (37—90),
treated by CAPD since a mean of 24 months (6—54): VU 591 578 ml/24
hr; UUC 1.49 1.48 mI/mm; UCC 2.73 3.30 mI/mm; CC 71 29
liter/week; UC 67 12 liter/week; Kt/V 1.81 0.36/week; IT 0.80
0.22; NPCR 0.96 0.20 g/kg/24 hr; P 7 3 g/24 hr; 0 81 25 g/24 hr.
NPCR is significantly correlated to the RRF, Kt/V, IT, UC and CC. The
multivariate analysis shows a significant effect of (Kt/V+G+P) on
NPCR (r = 0.74, Pc 0.0001), and a significant effect of (NPCR+CC) on
AIb (r = 0.47, Pc 0.0016). We conclude that the use of adequation tests
is useful in CAPD, particularly when the residual renal functions are
very low or absent, Periodic assessment would permit the optimization
of dialysis and the improvement of nutritional status measured by
NPCR. Glucose reabsorption has to be considered when analyzing
nutritional impalrment.
Renal side effects of triamterene-thiazide association. A report of nine
cases excluding urinary calculi. M. Bauwens, M. Baron, D. Picaud, Y.
Turpin, D. Patte, and G. Touchard, CHU Poitiers, CHR Niort, and
CHR Angouléme, France. We report nine cases of renal failure (acute,
6; chronic, 3) in nine Caucasian women treated with triamterene-
thiazide association (flA). Four etiologies of renal failure can be
distinguished among these nine cases: Three pre-renal acute renal
failures (ARF), two of them occurring in two patients treated for several
years by TTA and nonsteroidal anti-inflammatory drugs, and one
occurring in a patient receiving acetyl salicylic acid (250 mg/day) and
TTA. In these three cases, ARF was spontaneously reversed by four
weeks after diuretic therapy was discontinued. Renal biopsy was
performed in one case and was normal. One ARF with obstruction of
distal tubular lumens by triamterenc microlithiasis occurred after an
accidental overdosage. In this case, renal function returned to normal
after two months. Two cases of ARE secondary to immunoallergic
interstitial nephritis were discovered by renal biopsy. Renal function
remained abnormal in these two patients despite diuretic discontinu-
ance and corticosteroid therapy in one case (Ccr: 35 mI/mm). Two
chronic renal failures (CRF) persisted after withdrawal of TTA. In these
two cases, renal biopsy exhibited intratubular and interstitial triam-
terene crystals with foreign body-type granuloma. One CRF with
interstitial nephritis occurred in a 33-year-old woman receiving TTA for
eight years for idiopathic edema. Renal biopsy showed large interstitial
crystals with foreign body-type granuloma. Mter withdrawal of flA,
renal function improved significantly with a serum creatinine level
decreasing from 400 amol/liter to 120 rmol/liter. Conclusions: ARF
induced by TTA alone or in association with prostaglandin inhibitors is
well-known. On the contrary, chronic interstitial nephritis has not yet
been reported with flA. This study shows that triamterene can induce
chronic interstitial lesions with interstitial crystals and foreign body-
type granuloma.
Detection of hepatitis C virus Infection by polymerase chain reaction
among hemodialysis patients. Yvon Berland, Bertrand Dussol, Colette
Chicheportiche, Jean-Francois Cantaloube, Philippe Biagini, and Pa-
trice Bert hezene, Hemodialysis Unit, Sainte-Marguerite Hospital,
Marseille, France. One hundred twenty-nine patients on regular hemo-
dialysis at our institution were evaluated for the presence of hepatitis C
virus (HCV) infection. Thirty-eight (29%) had detectable antibodies to
HCV using second-generation enzyme-linked immunosorbent and re-
combinant immunoblot assays. Among positive patients (HCV+),
twenty-eight were tested for direct detection of the HCV genome by
Polymerase Chain Reaction, as also were ten negative patients
(HCV—). Twelve HCV+ patients (42%) had detectable RNA HCV in
plasma. No HCV— patient had viremia. In addition, we compared the
38 HCV+ to 32 HCV— patients matched for age, sex, duration of
hemodialysis, history of blood transfusion, serological markers of
hepatitis B virus, acute and chronic liver disease, and cirrhosis. On
retrospective analysis statistically significant associations with HCV+
were duration of hemodialysis (P = 0.006), blood transfusions (P =
0.003), acute and chronic liver disease (P = 0.006 and 0.02, respective-
ly), and cirrhosis (P = 0.05). However, multivariate analysis does not
permit distinguishing the two populations. When we compared in the
HCV+ group viremic or non-viremic patients with the same parame-
ters, no statistical difference appeared. These results reveal that about
40% of HCV+ hemodialysis patients in fact have HCV infection.
Medical consequences of HCV infection in this population were not
characterized.
Rise in serum creatinine induced by phenacemide without renal failure:
Inhibition of creatinine transmembrane transport? R. Cahen, A. Martin,
B. François, P. Trolliet, and P. Louisot, Division of Nephrology,
Lyon-South University Medical Center, and INSERM U 189, Lyon-
South School of Medicine, Oullins, France. Two patients treated with
the anticonvulsant drug, phenacemide, at the dosage of 900 mg/day,
were investigated for markedly increased serum creatinine (187 and 220
rmoWiter) and decreased creatinine clearance values (54 and 40 ml/
mm/I .73 m2). Blood urea nitrogen and glomerular filtration rate as
determined by '251-iothalamate clearance were normal in both patients.
There was no evidence of renal disease. Enzymatic determinations
ascertained an elevation of true creatinine and further in vitro studies
excluded an analytical interference of phenacemide with the Jafft
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reaction. After discontinuation of the drug, phenacemide concentra-
tions became undetectable within two days, but it took seven to 14 days
for serum creatinine (86 and 81 smo1Iliter) and creatinine clearance (85
and 103 ml/min/1.73 m2) to return to normal values. The serum
creatinine increase under phenacemide is much higher than that re-
ported with cimetidine or trimethoprim (10—40%). Thus, inhibition of
tubular secretion of creatinine is not a priori sufficient to explain the
effect of phenacemide. All six rats that were given phenacemide had
serum true creatinine levels significantly higher than those of controls,
suggesting that creatinine increase under phenacemide is a general
biological reaction. In vitro creatinine influx into red blood cells was
inhibited by phenacemide in a dose-dependent way. This inhibition
already appeared at the concentration 0.1 mmol/liter, which was the
range of serum phenacemide concentrations determined in both pa-
tients. Therefore, it may be suggested that the rise in serum creatinine
under phenacemide is due to an inhibition of transport, leading to a
decrease in the distribution volume of creatinine. These findings raise
the issue of creatinine transmembrane transport mechanisms. Phenace-
mide could be an interesting tool for further experimental studies on
creatinine metabolism.
Differential effect of antilymphocyte globulins on lymphocytic molecules
implicated in the rosette phenomenon. E. Cassuto-Viguier, G. Bernard-
Pommier, M. Ticchioni, J.R. Mondain, D. Barn/Ion, and A. Bernard,
Service de Nephrologie, Hôpital Pasteur, and Laboratoire d'Immunol-
ogle, Hôpital de l'Archet, Nice, France. The CD2 molecule alone
seems to be able to permit rosette formation, but the E2 molecule has
recently been demonstrated to be present on T lymphocytes and to be
implicated in the rosette phenomenon. To investigate the effect of
antilymphocyte globulins (ALG) on these lymphocytic molecules, CD2
and E2 positive lymphocytes were monitored by FACS analysis during
ALG treatment of kidney transplanted patients. Results were confirmed
by using CD2 and E2 transfected cells. FACS analysis in ALG treated
patients showed that CD2 positive lymphocytes dramatically disap-
peared, whereas a high percentage of E2 positive cells persisted. We
demonstrated that these E2 positive and persisting cells bore B lym-
phocyte specificities. Studies using transfected cells confirmed that
ALG contain a high activity directed against CD2 molecules, but none
against E2 molecules.
Study of skeletal muscle energy metabolism in patients with advanced
renal failure by 31P-NMR spectroscopy. Effects of a very-low protein diet
supplemented with amino acids. C. Combe, M. Biran, E. Peuchant, G.
Raffard, M. Clerc, P. Canioni, and M. Aparicio, Service de Néphrol-
ogie, Unite de Resonance Magnetique, Laboratoire de Biochimie,
Universite Bordeaux II et Hôpita/ Pellegrin, Bordeaux, France.
Chronic renal failure (CRF) is accompanied by several metabolic
abnormalities, including modifications of energy metabolism. Muscle
energy metabolism was evaluated in 13 patients with CRF (EDTA 51Cr
clearance 11.2 3 mI/mm) and 13 normal control subjects (Ctl).
Intracellular pH (pHi), concentrations of ATP, phosphocreatine (Pcr),
and inorganic phosphate (Pi) were obtained on a Siemens whole body
Magnetom Spectrometer, operating at 1.5 Tesla. The signal was recov-
ered from a localized area in the calf muscle at rest, during mild exercise
of three minute duration, and during recovery, pHi was not different at
rest in CRF patients and Ctl, nor during exercise, while it was
significantly lower during recovery in CRF patients (P < 0.001). Cr
muscle content was lower during exercise and recovery in CRF patients(P < 0.001), as was ATP. Intracellular Pi was slightly higher during
recovery in CRF patients. Since low-protein diets (LPD) in CRF
patients are able to correct extracellular metabolic acidosis, hyperphos-
phatemia, and other metabolic abnormalities linked to uremia, the
effects of a LPD (0.4 g protein/kg/day) supplemented with essential
aminoacids and their ketoanalogues were assessed on muscle energy
metabolism after six months of LPD in nine patients. LPD lowered Cr,
presumably in relation with the decreased intake of exogenous creatine.
Muscle ATP content was also further decreased. Intracellular pH was
significantly higher during recovery after six months of LPD. In
conclusion, for mild exercise, there was evidence in CRF patients of
prolonged slight intracellular acidosis during recovery, with decreased
1Crconcentrations compared to normal control subjects. LPD partially
corrected the intracellular acidosis and the increased intracellular
phosphate concentration demonstrated in CRF patients during recov-
ery, but LPD decreased muscle Pc and ATP concentrations.
Effect of cyclosporine A (CsA) upon the synthesis of cyclooxygenase by
rat smooth muscle cells. V. De Precigout, D. Daret, L. Potaux, M.
Aparicio, and J. Larrue, Service d'Hémodialyse, Hôpital Pellegnin-
Tripode, Bordeaux, France. Several studies suggest that CsA interferes
with the metabolism of eicosanoids, but the mechanism of this interac-
tion remains very controversial. Our aim was to study the effect of CsA
upon cyclooxygenase synthesis in rat smooth muscle cells (SMC). SMC
were incubated in the presence of high concentrations of arachidonic
acid (AA), inducing an irreversible inhibition of the cyclooxygenase
activity. De novo synthesis of the enzyme was studied by a 24 hour
incubation in the presence of increasing concentrations of CsA (0—500
ng—I0 pg). The transformation of '4CAA was determined after a 30
minute incubation and extraction of the organic phase by thin layer
chromatography and analysis by scanner. Results are presented in
Table 1.
Table 1. Percent of radioactivity detected for various metabolites of
AA
CsA in
medium 6KPGF1a HETE
Total of
metabolites AA
0 9.3 1.7 5.1 1.8 20.5 5.4 71.3 6.2
500 ng/ml 8.9 1.9 3.9 0.3k 16 2.6 78.1 2.6a
10 sg/ml 6.5 12b 3 0.4" 12.8 27b 79.8 2.9l
a P < 0.05; b p < 0.01
In the absence of CsA, the metabolites of AA account for 20.5% of the
radioactivity instead of 16% and 12.8% with 500 ng/ml and 10 /ml of
CsA. These results demonstrate that CsA interferes with the synthesis
of cyclooxygenase, and that this inhibition is partially dose related.
Slowing parathyroid secretion suppresses urinary phosphate loss in
kidney transplant recipients. G. Dumoulin, B. Hory, M. T. Henriet,
N.U. Nguyen, J. Regnard, C. Bresson, E. Legrand, J.P. Wolf, S.
Bert helay, and Y. Saint-Hillier, Laboraroire de Physiologie Médicale et
Service de Nephrologie, CHU, Besan con, France. Persistent hyper-
parathyroidism and impaired tubular reabsorption of phosphate (P) are
common after kidney transplantation. To assess the role of parathor-
mone (PTH) in urinary loss of P, we studied the effects of an oral
calcium load in 16 patients (4 females) aged 20 to 61 years, who had
benefited from kidney transplantation six to 167 months earlier. Their
creatinine clearance was higher than 60 mI/mm/I .73 m2 and stable for
five months at least, and their plasma calcium level was lower than 2.6
mmol/liter. Patients were treated with two immunosuppressive agents,
low dose steroids, azathioprine and/or cyclosporine, and none of them
had received vitamin D for six months, nor any P binder agent. On
study day, blood and urine samples were collected in fasting state at
8.00 a.m. (baseline), and hourly during four hours following the oral
intake of one gram of calcium (Ca Forte, Sandoz). From these samples
we determined P urinary excretion, tubular reabsorption rate of P
(TRP), P clearance, renal threshold of P (TmP/GFR), plasma P, Ca,
PTH (IRMA, Nichols), and nephrogenous cyclic AMP (NcAMP, RIA,
INCSTAR). Significant statistical changes were assessed by two-way
ANOVA for repeated measures, followed by Scheffé's test. At base-
line, urinary excretion of P was abnormal, since urinary P stand at the
upper limit of normal range (0.99 0.27 mmol/hr; mean SD), whereas
plasma P was slightly decreased (0.92 0.13 mmol/liter). Further, P
clearance was high (17.2 5.4 mI/mm/I .73 m2), in agreement with low
values of TmP/GFR (0.72 0.14 mmol/liter) and TRP (77 8%). In
addition, PTH secretion was high (PTH = 91 56 pg/mI, normal range
10—65; NcAMP = 3.3 1.3 nmol/l00 ml GFR, normal range 0.5—2), and
plasma calcium was normal (2.25 0.09 mmol/liter). The oral calcium
load induced a slight increase in plasma calcium (2.44 0.12 after 2
hours, P < 0.001) and a clear-cut slowing of parathyroid secretion (PTH
= 51 25 after 1 hour, P <0.001; NCAMP = 2.0 1.3 after 3 hours,
P < 0.001). Urinary excretion of P was divided by 2(0.46 0.22 after
3 hours, P < 0.001) whereas P clearance, TRP, and TmP/GFR all
resumed normal values (respectively 8.4 4.1 after 3 hours, 88 5
after 4 hours, and 0.93 0.21 after 4 hours, P <0.001); there was a very
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slight change in plasma P (0.88 0.14 after 1 hour and 0.94 0.12 after
4 hours, P < 0.05). In summary, our study showed that in kidney
transplant recipients oral calcium intake (1 g) causes a clear-cut slowing
of parathyroid activity and simultaneously restores normal tubular
reabsorption of phosphate. These results further suggest that hyperse-
cretion of parathyroid hormone might be a key factor of phosphate
depletion due to lack of renal phosphate handling after kidney trans-
plantation, even if other independent factors may also contribute (such
as steroids, cyclosporine, and tubular transport disorders).
Analysis of the protein content of five kidney stones with different
composition. B. Dussol, M. Daudon, P. Dupuy, R. Michel, Y. Berland,
J.C. Dagorn, and J.M. Verdier, HOpital Sainte-Marguerite, Marseille;
Hdpital Nec/cer, Paris, and INSERM U315, Marseille, France. The aim
of this study was to characterize the protein matrix of five kidney stones
with the following composition: calcium oxalate monohydrate (type I),
calcium oxalate dihydrate (type II), uric acid (type III), struvite (type
IV) and cystine (type V). After extraction of calcium salts, the proteins
were run in SDS-PAGE and analyzed by Western blot experiments
using specific antibodies. In all types, the most abundant protein found
was albumin, al-acid glycoprotein, al-microglobulin, immunoglobu-
lins, apolipoprotein Al, transferrin and al-antitrypsin were also present
in the five types of calculi. /32-mieroglobulin was only found in types I,
II and III. Furthermore, using antibodies to pancreatic lithostathine, an
inhibitor of CaCO3 crystal growth in pancreatic juice, we detected a
protein immunologically related in all types of stones. Conversely, we
failed to detect the retinol-binding protein, eaeruloplasmin, or hapto-
globulin and, surprisingly, the Tamm-Horsfall protein (THP), the most
abundant protein in normal urine. From these results, it is concluded
that: (i) kidney stones contain a protein immunologically related to
pancreatic lithostathine which we called renal lithostathine for reasons
described elsewhere; (ii) the THP is probably not a constituent of
kidney stones; (iii) not all the proteins of normal urine are present in
stone protein matrix. It is therefore possible that the proteins present
within stones play a specific role in kidney stone formation particularly
with regard to the well-known calcium- and protein-binding properties
of human albumin.
Donor related non-Hodgkin lymphoma in a renal allograft recipient. L.
Fromentin, G. Meduri, 0. Lana, C. Hiesse, and B. Charpentier,
Service de Néphrologie, Hdpital de Bicdtre, Bicétre, France. Mrs.
G.P., a 60 year old patient, developed an N.H. lymphoma on her renal
graft eight months after transplantation for renal insufficiency second-
ary to bilateral renal hypoplasia. The donor was a 20 year old woman
deceased of cranial trauma. After an uneventful post-surgical recovery
the renal function was normal for eight months under conventional
immunosuppression, then deteriorated progressively. A renal sean and
arteriography revealed the presence of a hylar hypervascular mass on
the graft which was removed 10 months after transplantation. A tumor
of 6 x 3 cm surrounding the renal vessels was found; it slightly
infiltrated the renal tissue and was constituted of large lymphomatous
cells. An extrarenal diffusion was excluded by careful clinical exami-
nation, complete with a brain scan, bone marrow biopsy, lymphography
and chest x-rays. A cycle of antineoplastic therapy (Endoxan-Vineris-
tine-Prednisone) was started, followed by local irradiation (30 grays);
the patient is still disease free at follow-up 18 months after graft
removal. Immunohistological analysis of the tumor with a panel of
monoclonal antibodies revealed a B-cell origin and monoelonal 1gM-K
expression. No evidence of EBV or other viral infection was found, and
VNTR (variable numbers of tandem repeats) analysis showed that the
malignant lymphocytes were donor-derived. Transplanted malignancies
are rare nowadays, donors with cancers being systematically excluded
except those with low-malignancy skin cancers or primitive brain
tumors; their prognosis is good when confined to the graft, and the
outcome is worse in the presence of distant metastases, even after
withdrawal of anti-rejection therapy, graft removal and anti-neoplastic
treatment. Lymphoproliferative disorders are conversely more frequent
in immunocompromised transplant recipients than in the normal popu-
lation; they range from relatively benign polyelonal B-cell prolifera-
tions, mostly virally induced, to non-Hodgkin lymphomas requiring
anti-neoplastic therapy. In the reported case no evidence of lymphoma
was found in the donor: the hypothesis of transformation of the donor's
lymphocytes under prolonged stimulation by the host antigens must be
considered. The importance of accurate follow-up of transplant recipi-
ents must be stressed: immunophenotyping of tumors, search for viral
antigens and tumoral caryotype analysis should always be performed to
define risk groups and the treatment of choice.
Renal lesions observed in 240 Black African patients Infected by the
human immunodeficiency virus (HIV). D.A. Gnionsahe, A. Kadio, and
B.M. Boka, Nephrology Department, University Teaching Hospital of
Yopougon, Abidjan; Infectious Diseases Clinic, University Teaching
Hospital of Treichville, Abidjan; Pathological Anatomy Laboratory,
University Hospital of Cocody, Abidjan, Côte d'Ivoire, Africa. To
assess the importance of renal anatomopathological lesions associated
with infection by HIV, 240 autopsies were carried out on seropositivc
patients, (group I) and 43 autopsies on seronegative patients (group II)
from February to November 1991. Group I comprised 183 men and 57
women and group II, 30 men and 13 women. The average age was from
38 3 years in group I and 38 4 years in group II. The classification
of group I patients according to the type of virus was 163 cases (68%) of
HIV1, 27 cases (11%) of HIV2, and 50 cases (21%) of HIV1 + HIV2.
The examination of the kidney under optical microscope revealed the
following results: Group I: 92 histologically normal kidneys, 148 patho-
logical kidneys, the main lesions being constituted by acute tubular
necrosis, 39% (N = 59); tuberculosis, 33% (N = 50); pyelonephritis,
14% (N = 21); cryptocoecocis (N = 5), acute interstitial nephritis (N =
4), leukemia (N = 2), C.M.V (N = 1), nocardiosis (N = I) and amylosis(N = 1) together, represented 9% of the lesions. Glomeruloscierosis
was found in seven patients and constituted 4% of lesions observed.
Group II: 30 histologically normal kidneys, 13 pathological kidneys with
lesions constituted by glomeruloselerosis (N = 5) as a result of
malignant hypertension (N = 2), diabetes (N = 2) and one case of
undetermined etiology; interstitial nephritis (N = 3), pyelonephritis (N
= 2), glomerulonephritis (N = I) and tuberculosis (N = 1). Conclusions:
Acute tubular necrosis, tuberculosis and the acute pyelonephritis
constituted the main histological renal lesions observed among the
seropositive patients. Glomeruloselerosis represented 4% of the renal
lesions of seropositive patients and 38% of those of seronegative patients.
Color Doppler sonography (CDS) evaluation in the first month after
renal transplantation (Tx). J. Hacini, P. Romy, K. Maachi, C. Broyet,
C. Veyret, and F. Berthoux, Service de Néphrologie, Dialyse et
Transplantation Rdnale, Service de Radiologie, HOpital Nord, Saint-
Etienne, France, Classical ultrasonograpby (US) is widely used and
permits accurate diagnosis of some kidney graft (KG) dysfunetions. We
prospectively evaluated 61 renal Tx (43 M, 18 F) with additional CDS
(Color Doppler Sonography). We detected early arterial thrombosis in
four patients (from multiple graft arteries and partial infarction; no renal
vein thrombosis). Our aim is to discriminate between the three most
common situations: acute rejection (R); acute tubular necrosis (ATN);
and stable graft function (5). We used a Toshiba SSA 270A with a 3.75
MHZ transducer and analyzed the following parameters: renal artery
maximum systolic frequency shift (RA-MSS), interiobar artery-MSS
(ILA-MSS), interiobar artery minimum systolic frequency shift (ILA-
mSS), renal artery-resistive index (RA-RI), and interiobar artery-RI
(ILA-RI). We have done 39 PDS for 39 R with 39 biopsies in 32 patients
(group R); 16 PDS for 16 ATN (or prolonged) with 16 biopsies in 12
patients (group ATN), and 64 PDS in 47 patients before or after
recovery or with no dysfunction (group 5). The results are respectively
in the 5, R and ATN groups: —m = 0.64 0.28 (sn) m/sec vs. 0.54
0.34 (SD) vs. 0.53 0.12 for RA-MSS (NS); —m = 0.23 0.05 vs. 0.20
0.08 vs. 0.18 0.06 for ILA-MSS (NS); —0.08 0.02 vs. 0.07 0.12
vs. 0.05 0.03 for ILA-mSS (NS); —m = 0.72 0.09 (SD) vs. 0.81
0.11 (P = 0.01) vs. 0.75 0.11 (NS) for RA-RI; and —0.65 0.09 vs.
0.80 0.16 (P 0.01) vs. 0.75 0.14 (P =0.01) for ILA-RI. We could
not discriminate between R and ATN; however, RI and systolic
frequency shift are lower in the ATN Group. We conclude that CDS is
a reliable technique for KG proximal vaseularization evaluation. In-
creased RA-RI and/or ILA-RI are diagnostic of renal dysfunction due to
either ATN or rejection. However, at this point, graft biopsy remains
necessary for accurate diagnosis and adequate treatment.
Outcome and consequences of pregnancy in women with chronic renal
failure. P. Jungers, A .M. Blanchard, P. Houillier, D. Forget, and J.P.
Grunfeld, Department de Nephrologie, Hopital Necker, Paris, France.
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Fetal outcome and possible adverse effects of pregnancy (P) on mater-
nal renal function in women with chronic renal failure (CRF) are still
debated. Fetal and maternal prognosis has been reported to be com-
promised when plasma creatinine concentration (Per) at conception is in
excess of 160 molIliter. In order to re-evaluate whether this limitation
is still valid, we retrospectively analyzed the course of 27 P started from
1970 to 1991 in 19 women with primary renal disease in whom Cr at
conception was  125 tmolIliter. In eight of these patients, 10 Un-
planned P without joint nephrological and obstetrical surveillance all
ended in fetal death, including three first-trimester abortions (1 thera-
peutic for severe HBP, 2 spontaneous in patients with PCr 258 and 504
smolI1iter), and seven fetal deaths in utero (FDIU) from the 21st to the
33rd gestational week (OW) in patients with Cr ranging from 140 to 270
mol/liter. An accelerated course of maternal CRF occurred in five of
these patients. By contrast, 17 planned P (in 11 women) benefited from
prospective joint nephrological and obstetrical care. Fetal outcome was
essentially successful with only two fetal deaths (FDIU at 32nd and 27th
OW respectively in a patient having reflux nephropathy and severe
HBP, with Cr 133 and 168 imol/liter), whereas the other 15 P (88%)
started with 'ICr at conception ranging from 125 to 225 moII1iter ended
in live birth, with a mean neonate weight of 2534 g (range 1200—3280 g).
Prematurity was observed in eight cases (47%) and cesarean section
was performed in seven cases (41%). An accelerated course of maternal
renal disease was observed in four patients, leading to end-stage CRF
within four to five years in three cases (2 refiux nephropathy, one
polycystic kidney disease) with 1Cr 160, 212 and 225 molIliter, and
within two years in a patient with Berger's disease and severe HBP with
Cr 160 mol/liter at conception. We conclude that a successful and
uneventful outcome of P may now be expected in a patient with CRF
due to non-systemic renal disease when 1'Cr at conception does not
exceed 200 to 220 molIliter, thanks to recent progress in fetal moni-
toring and neonatology, whereas there still is a high risk of poor fetal
and maternal prognosis beyond this limit. Close cooperation between
nephrological and obstetrical teams from the beginning of P is manda-
tory to provide the best chance for successful outcome.
Bacteremia in chronic hemodialysis patients. A multicenter prospective
study. M. Kessler, B. Hoen, D. Mayeux, D. Hestin, C. Fontenaille, and
the Cooperative Group on Bacterial Infections in Hemodialysis, De-
partment of Nephroiogy, University of Nancy, Vandoeuvre, France. A
prospective epidemiologic survey of bacterial infections in chronic
hemodialysis patients was conducted from September 1, 1989, to
February 28, 1990, in 27 dialysis units. Of the 1455 patients enrolled in
the study, 55 presented 63 episodes of bacteremia (incidence 0.7/100
patient-months). The portal of entry was the vascular access in 50.8% of
the episodes. The causative microorganisms were most often gram-
positive cocci (69.8%). Twenty-three percent of the bacteremic patients
had a serum ferritin > 100 pg/liter versus 7% of the non-bacteremic
infected patients (P = 0.005); 39.7% of the patients had undergone a
surgical operation during the month preceding the bacteremia. Eight
patients had a recurrence during the study period and eight had a
metastatic localization: spondylodiscitis 2, septic pulmonary embolus 2,
endocarditis 1, arthritis 1, liver abscess 1, and endophalmia 1. Sixty-six
percent of the episodes required a hospitalization that lasted an average
of 20 days. Mortality rate was 6.3%. This prospective study showed a
trend towards a reduction of incidence and mortality of bacteremia in
patients on chronic hemodialysis.
Comparison of calcitriol (1,25D) and 22-OXA-l,25D (OCT) effect on
PTH secretion and intestinal Ca transport in normal and chronic renal
failure (CRF) rats. M. Kubrusly, C. Hanrotel, E.-R. Gagne, G. Je-
henne, B. Lacour, and T.B. Drfl eke, INSERM U. 90, Hôpital Necker,
Paris, France. The l,25D analog, OCT. has previously been shown to
decrease parathyroid hormone (PTH) secretion in vivo in rats with mild
renal failure, and to inhibit prepro-PTH mRNA in normal rats without
inducing hypercalcemia. Therefore, a selective effect of this analog on
the parathyroid gland has been proposed. The purpose of the present
study was to compare the effect of OCT to that of 1 ,25D on duodenal Ca
transport and plasma PTH levels in normal rats and in rats with severe
CRF and hyperparathyroidism. Wistar rats underwent 5/6 nephrectomy
(Nx) and were fed a phosphate-rich diet (1.2% P, 0.6% Ca) during the
four weeks after Nx. Normal rats received standard lab diet (1.2% Ca,
1% P) during one week. All the animals received an i.p. injection of
either vehicle solution, OCT or I ,25D (0.3 pg/rat/day) 48 and 24 hours
before sacrifice. Duodenal transport of Ca was measured by the everted
gut sac technique (S/M ratio), duodenal CaBPSk content and PTH,_34 by
RIA, and blood ionized Ca [Ca2] by [Ca2] probe. Results were as
follows (means SaM):
CRF
rats N
Creat
junoi/liter
Ca
miic S/M
CaBP
pg/mg
PTH
pg/mi
control 8 162 22 1.02 0.03 2.8 0.4 2.4 0.7 897 74
l,25D 8 171 19 1.23 0.04a 7.0 0.6a 8.9 1.3" 344 75
OCT 11 160 13 1.10 0.02" 3.7 0.3 8.5 l.2' 632 46C
Anova: a p <0.001, l,25D vs. control and OCT; b P <0.05, OCT vs.
control; C P < 0.001, OCT vs. control; d p < 0.002, l,25D and OCT vs.
control.
Normal Creat Ca CaBP PTH
rats N p.mol/iiter mM S/M pg/mg pg/mi
control 6 42 2 1.35 0.02 5.6 0.4 8.2 0.8 19.2 1.5
l,25D 9 44 1 1.48 0.04a 7.3 0.5a 18.2 13b 16.3 0.3'OCT 9 43 1 1.38 0.01 5.3 0.4 10.6 0.8 15.5 0.8C
Anova: P < 0.01, a 1,25 vs. control and OCT, P < 0.001; b 1,25 vs.
control and OCT. P < 0.05, C 1,25 and OCT vs. control.
In conclusion, OCT decreases plasma PTH levels in normal rats to the
same extent as l,25D without augmenting duodenal Ca transport or
calcemia. In contrast, in rats with advanced CRF and severe hyper-
parathyroidism, OCT leads to a less marked decrease of plasma PTH
than 1 ,25D, increases CaBP in a similar fashion, but does not stimulate
duodenal Ca transport. Blood [Ca2] increases less than with I ,25D. It
therefore appears that this 1 ,25D analog is less efficacious in controlling
severe secondary hyperparathyroidism than I ,25D itself. Moreover, in
the dosage used, OCT is capable of stimulating an increase in blood
[Ca2'i without enhancing intestinal Ca transport.
Immunoallergic acute renal failure (ARF) in children after a short-term
non-steroidal anti-inflammatory treatment. B. Lantz, P. Cochat, J.L.
Bouchet, and M. Fischbach, Hôpitai Avicenne, Bobigny; Hôpital
Edouard-Herriot, Lyon; CTMR, Bordeaux; Hôpitai Hautepierre, Stras-
bourg, France. Different mechanisms involving adverse effects on renal
function are widely described in adults with non-steroidal anti-inflam-
matory drugs (NSAID). In the last ten years, we observed seven cases
of ARF due to immunoallergic interstitial nephritis in children. A
recommended dose of short-term niflumic acid (NA) was prescribed for
ear, nose and throat disorders. Clinical renal symptoms (edema, oligo-
anuria, hypertension) appeared between two and six days after the
initial administration. Three patients previously received the drug.
Hypersensitivity signs (fever, skin rash, eosinophilia) were present in
five cases, leukocyturia in four cases, and hematuria in six cases. Three
children were anuric.
Case Sex Age Duration Creatinine Proteinuria Recovery
I M 11 months 4 days 560 mol/liter 0.32 g/liter 15 days
2 F 6 years 3 days 538 smol/liter 1.00 g/liter 7 days
3 M 8 years 2 days 800 mo1/liter 4.30 g/liter never
4 F 7 years 3 days 750 mol/liter 5.00 g/liter 28 days
5 F 12 years 2 days 246 JLmol/liter 0.30 g/liter 10 days
6 M 8 years 5 days 176 mol/liter 0 30 days
7 M 2 years 2 days 150 mol/liter 0.20 g/liter 4 days
Renal biopsy generally showed interstitial lesions with lymphocyte,
eosinophil and plasma cell infiltrates without tubular cell necrosis.
Glomeruli were normal on light microscopy and immunofluorescence.
Electron microscopy showed extensive podocyte fusion in two children
(3 and 4), who also had nephrotic syndrome (NS). ARF disappeared
within three weeks after NSAID withdrawal, except in patient 3 whose
renal failure was non-reversible, despite intensive methylprednisolone
therapy. Patient 4 developed severe NS which disappeared in a few
468 Abstracts
weeks after a five-day NA treatment. Six months later ARF occurred
after a second NA administration, which was totally reversible in four
weeks. Five months later, a third inopportune NA administration led to
chronic renal failure. Alport syndrome was discovered and regular
hemodialysis became necessary. ARF is very rare in children treated
with niflumic acid. In children as in adults, NA prescription must be
wisely evaluated considering previous administration(s) and renal func-
tion.
Prevention of cyclosporin A (CsA)-induced vasoconstriction of human
glomeruli with prostacyclin analog iloprost. E. Le Guen, B. l'Azou, D.
Morel, J. Cambar, M. Aparicio, and L. Potaux, Department of
Nephrology, Hôpital Pellegrin-Tripode, Bordeaux, France. The aim of
this study is to show the capacity of the prostacyclin analog Iloprost to
prevent cyclosporine-induced vasoconstriction on isolated human gb-
meruli. Glomeruli were isolated from human cortex kidney issued from
total nephrectomy for polar cancer. Non-tumoral tissue was cut off and
incubated in buffered Hank's solution at 4°C. The cortex was dissected
and sifted through different sizes of sieves, 225, 175 and 120 js.
Glomeruli were collected on the 120 js sieve and reincubated in buffered
Hank's solution. Samples of glomeruli were photographed at T0 (mag-
nification >< 40) and were then coincubated with either CsA (106
mole/liter), Iloprost (106 mole/liter) or CsA with Iloprost, and photo-
graphed at one, two and five minutes (T1, T2 and T5). Area of glomeruli
was measured with a computerized videoanalyzer. Variations in gb-
merular areas are expressed as mean standard deviations from T0
(100%). Paired Student's f-test was used for statistical analysis. Results:
There is a significant decrease in glomerular areas with CsA alone (T1:
91.96 4.17; T2: 93.2 3.92; T5: 92.56 2.91). There is little but no
significant increase in glomerular areas with Iloprost alone at T1 and T5
(T1: 102.19 3.04; T2: 101.34 1.45; '1's: 102.20 3.52) and no
variation with CsA ÷ Iloprost(T1: 100.81 2.78;T2: 101.43 2.53;T:
100.36 2.86). Conclusions: CsA-induced vasoconstriction on human
glomeruli is confirmed and can be prevented with the Prostacyclin
analog Iloprost in vitro.
Fungal peritonitis remains a serious complication in patients on chronic
peritoneal dialysis. C. Michel, L. Courtavault, P. Roux, and F. Mignon,
Services de Nephrologie et de Mycologie, Hopital Tenon, Paris,
France. Recent progress in peritoneal dialysis (PD) connectology has
decreased the incidence of peritonitis, improving diagnosis, and therapy
has significantly lowered morbidity. However, fungal peritonitis is
being increasingly recognized. The aim of this study was to review the
clinical and microbiologic features and the outcome according to
treatment modality of fungal peritonitis which occurred among 325
patients undergoing chronic PD in our center between 1/1/84 and 1/1/92.
Twenty patients (6.1%) developed fungal peritonitis. Their mean age
was 65.1 2.7 years (41—82). The mean duration of PD before
developing fungal peritonitis was 20.6 4.1 months (1—72). Nineteen
patients were treated by CAPD (16 with non-disconnect systems, 3 with
disconnect systems), and one patient by IPD. Number of prior bacterial
peritonitis was 2.7 0.6 (0—9). Eighteen patients received intraperito-
neal therapy in the month prior to development of fungal infection
(antibiotics for bacterial peritonitis, 16 patients; insulin, 5 patients).
Three patients were on immunosuppressive therapy. Initial gram stain
of the dialysate identified fungi in six cases. In the other 14 cases, only
dialysate cultures revealed fungi, with a delay of one to seven days.
Candida species accounted for 75% of all cases of peritonitis, with
Candida albicans by far the most common isolate; other species
(Torulopsis glabrata, Rhodotorula rubra, Geotrichum candidum, As-
pergillus fumigatus, Acremonium obclavatum) were isolated once each.
In five cases, mixed cultures were detected: three associations with
enteric flora, two with environmental flora. A wide variety of antifungal
therpy was used during the first years; however, since June 1989, a
combination of five flucytosine (i.p. and/or i.v.) and oral fluconazole
was systematically used (7 patients). Two patients died from life-
threatening underlying illnesses within the first five days following the
diagnosis of fungal peritonitis [end-stage cardiac failure (1), extensive
neoplasia (1)]. Among the other 18 patients, only one was cured without
discontinuation of PD, the other 17 had to stop at least temporarily PD
because of persistent turbid PD fluid with pentoneal ultrafiltration loss
within two to 15 days after peritonitis diagnosis. Seven of them had
been treated with 5 flucytosine + fluconazole. The mean duration of
hospitalization was 24 14 days (0—45). Transfer to hemodialysis was
definitive in 13 cases (death within the first three weeks on HD, 3;
personal or medical staff choice, 8; peritoneal adhesions making further
peritoneal catheter replacement impossible, 2). In four patients, PD was
reinstituted [using the same catheter (2 cases), after replacement of a
new peritoneal catheter (2 cases)]. In our experience, fungal peritonitis
is an uncommon PD complication, preceded by intraperitoneal antibac-
terial therapy for bacterial peritonitis in 80%. Progress in PD connec-
tology should decrease its incidence. Despite new antifungal agents, it
remains a serious complication with high morbidity.
TNFa in kidney transplant rejection: In situ hybridization study. D.
Morel, E. Normand, J.P. Merlio, E. LeGuen, M. Aparicio, L. Potaux,
and B. Bloch, Service de Néphrologie-Transplantation Rénale, Hopilal
Pelle grin, Bordeaux, France. Macrophage infiltration of rejecting kid-
ney transplants correlates with poor prognosis. On the other hand,
TNFa is involved in many inflammatory and immunological phenomena
and mediates a great part of macrophage toxicity. We thus evaluated
the expression of TNFa mRNA by in situ hybridization in six rejected
kidney transplants using a radiolabeled TNFa-cDNA probe. In the five
severely rejected grafts, TNFa mRNA is expressed in some monomor-
phic infiltrating cells, mostly located in the deepest part of the cortex
and around the tubules, occasionally in the walls of very thickened
vessels, and generally outside of the monomorphic lymphocytie infil-
trate. Labeled cells were medium-sized, with large lobular nuclei,
consistent with the monomorphic or macrophagic lineage. These
TNFa-cDNA binding cells did not bind other non-relevant probes.
These cells probably synthesize TNFa protein, as they are concomi-
tantly recognized by an anti-TNFa antibody. This antibody also binds
with a number of gbomerular endothelial and tubular epithelial cells,
which do not express the TNFa gene. These cells are likely target cells
for TNFa. TNFa-cDNA or anti-TNFa antibody binding cells could not
be detected in the sixth graft, in which rejection was much milder, nor
in normal kidney. The chronology of TNFa synthesis during develop-
ment of rejection remains to be determined. This could open the field
for specific therapies such as anti-TNFa monocbonal antibodies or
inhibitors of TNFa synthesis.
OKT3—Induction immunosuppressive therapy decreases the incidence
of early graft rejection in HLA-identical renal transplant recipients. M.P.
Morin, C. Legendre, L. Chatenoud, M. Lacombe, and H. Kreis,
Service de Transplantation, Hôpital Necker, Paris; INSERM U25,
HOpital Necker, Paris; and Consultation de Chirurgie, Hopital Beau-jon, Clichy, France. Both patient and graft survival are considered to be
excellent in HLA-identical renal transplant recipients. However, to
achieve such results, steroids are necessary in a majority of patients, at
least temporarily. The aim of the present study was to retrospectively
assess the steroid-sparing effect of OKT3-induction immunosuppres-
sive therapy in HLA-identical renal transplant recipients as compared
to conventional therapy. We compared two groups of patients who
received an HLA-identical renal transplant from 1970 to 1990. Thirty-
six of them were initially treated with azathioprine alone (3 mg/kg/day).
Ten patients (group II) received a combination of azathioprine (3
mg/kg/day) and OKT3 as induction immunosuppressive therapy (5
mg/day for 30 days post-transplantation), Eight out of these 10 patients
were pre-operatively given a single i.v. infusion of 500 mg methylpred-
nisobone. Patient and graft outcomes as well as necessity to secondarily
introduce steroids were compared in these two groups of patients. All
patients had at least two years of follow-up. In group I patients,
high-dose steroids had to be introduced within two years post-trans-
plantation, because of biopsy-proven acute rejection in 25 cases (69%).
In contrast, in group II patients, steroids had to be introduced in only
three cases (30%) because of acute rejection. In group I patients, it was
possible to secondarily and definitively interrupt steroids after four
years post-transplantation in 16 out of 25 cases (64%). In group H
patients, OKT3 had to be interrupted after a mean of 15.1 days, ranging
from five to 30 days, because of anti-OKT3 immunization in five cases,
benign lymphoproliferative disorder in two cases, severe arthralgias in
one case, and acute renal failure of unknown origin in one case. There
was no statistically significant difference within the two groups with
regard to survival outcomes as well as renal function at two years.
According to our experience, it is therefore possible to significantly
reduce (P 0.03) the need for steroids and the incidence of early graft
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rejection after HLA-identical renal transplantation by using a combina-
tion of azathioprine and OKT3-induction therapy, without compromis-
ing patient and graft survival. Moreover, this short induction therapy
also avoids using cyclosporine and its potentially deleterious long-term
nephrotoxicity.
Successful kidney transplantation in a patient with microscopic poly-
arteritis and positive ANCA. M.P. Morin, E. Thervet, C. Legendre, B.
Page, H. Kreis, and L.H. Noel, Service de Transplantation, and
INSERM U90, Hópital Necker, Paris, Cedex France. ANCA have
been described in patients with Wegener's granulomatosis, microscopic
polyarteritis and idiopathic necrotizing and crescentic glomerulonephri-
tis. The presence of ANCA correlates closely with disease activity and
evolution. After renal transplantation, recurrence of WG is very un-
usual. One case with positive ANCA at the time of such recurrence has
been described and was associated with early graft failure. Therefore,
the question has been raised of the possibility of performing successful
renal transplantation in ANCA positive patients. We report on a patient
with microscopic polyarteritis and constantly positive ANCA through-
out transplantation course without recurrence of the initial disease after
two years. In 1987, microscopic polyarteritis was diagnosed in a
53-year-old white female who experienced polyarthralgia and skin rash.
She presented with proteinuria, microscopic hematuria, and renal
failure. Percutaneous renal biopsy demonstrated severe GN character-
ized by 80% of the glomeruli with sclerotic crescents without endocap-
illary proliferation; extensive interstitial cellular infiltration was present
without granuloma. Immunofluorescence staining showed no IgG de-
posits. No specific treatment was initiated. The patient experienced two
relapses of the skin and joint symptoms. Regular hemodialysis was
initiated 11 months after the occurrence of the disease. In January 1990,
cadaver kidney transplantation was performed. Immunosuppressive
regimen included prophylactic OKT3 during 16 days associated with
oral prednisone (1 mg/kg/day) and azathioprine (2 mg/kg/day). Cyclo-
sponne was started 10 days after transplantation at a daily dose of 6
mg/kg orally, then adjusted to maintain a trough level of 50 to 150 ng/ml
(whole blood, RIA with monoclonal antibody). Prednisone was then
tapered to reach 0.25 mg/kg daily one month after kidney transplanta-
tion. Two years after transplantation, the patient had experienced no
clinical signs of recurrent disease. Serum creatinine was stable around
110 molIliter. Treatment was unchanged. Routine renal biopsy per-
formed at this time showed neither crescents nor focal glomeruloscle-
rosis and epithelial proliferation. Tubules and interstitium were normal.
Throughout this period of time (before and after kidney transplanta-
tion), ANCA were constantly detected by both immunofluorescence
and enzyme-linked immunoadsorbent assay, with anti-myeloperoxy-
dase specificity. High titers, more than 30 arbitrary units (NI < 3 AU)
were found at the time of diagnosis and remained stable until transplan-
tation. After immunosuppression was initiated, ANCA were still
present but at a lower titer (18 AU). One may therefore ask whether
kidney transplantation is to be performed in a patient with positive
ANCA. In the present case, ANCA has been positive for two years
after kidney transplantation with no evidence of systemic or renal
relapse of initial disease, even on renal biopsy. This observation
illustrates that the presence of circulating ANCA without clinical signs
of relapse for several months may not be a contra-indication to kidney
transplantation.
Bacterial endocarditis glomerulonephritis (GN) with extracapillary
proliferation. Efficacity of antibiotic therapy alone. C. Orfila, A.
Modesto, J.C. Lepert, C. Goudable, and J.M. Suc, INSERM U133,
and Service de Nephrologie, CHU-Rangueil, Toulouse, France. Some
cases of bacterial infective GN can be associated with bacterial endo-
carditis. Rapidly progressive GN has been reported in 25 to 30% of
these cases. Immunosuppression was sometimes associated with anti-
biotic therapy. We report a case of extracapillary GN with bacterial
endocarditis that improved with antibiotic therapy alone. A 65-year-old
woman was admitted to the hospital because of purpura and renal
impairment. A heart murmur had been detected during an examination
53 years earlier (rheumatic fever). Five months before admission, a
purpura skin eruption was present over both lower extremities and a
skin biopsy demonstrated leukocytoclastic skin vasculitis two months
later. Mitral insufficiency was present. Laboratory data revealed nei-
ther renal impairment nor urinary abnormality. At the time of hospital-
ization in the Toulouse-Rangueil Hospital, fever was present and blood
cultures were positive for Streptococcus mitis (dental infection). Lab-
oratory data revealed hematuria, proteinuria and abnormal serum
creatinine (320 moles/liter). Serum levels of C3 and C4 were low;
cryoglobulins were detected. Serum levels of immune complexes (IC)
and gammaglobulins were high. A first renal biopsy was performed and
showed necrotizing GN with cellular crescents (50%) associated with
interstitial nephritis. By immunofluorescence. mesangial 1gM and C3
deposits were demonstrated. Fibrin was present in urinary spaces. By
electron microscopy, subendothelial and intramembranous deposits
were observed. The patient received antibiotic therapy with Amoxicil-
line-Gentamicine first, then Doxycycline-Erythromycine. The fol-
low-up showed persistance of purpuric lesions and cryoglobulins, while
hematuria, serum levels of creatinine, C3 and C4, and IC progressively
decreased. A second renal biopsy performed after three months showed
the presence of sequellar fibrous lesions associated with segmental
glomerulosclerosis (50%) and tubulointerstitial nephritis. Arterioles
were normal. Eight months after the hospitalization, cardiac insuffi-
ciency was present. The patient presented normal serum creatinine
level and urinalysis. Four years later, a valvular replacement was
performed. No abnormal serum creatinine and urinary levels were
present. In conclusion, we report a case of necrotizing GN with
extracapillary proliferation associated with a Streptococcus mitis endo-
carditis, in a patient with mitral insufficiency previously damaged by
rheumatic fever. The follow-up demonstrated improvement in renal
data after antibiotic therapy. Thus, stable renal function, after antibiotic
therapy alone, can be observed in rapidly progressive ON with bacterial
endocarditis associated with cellular crescents.
Use of erythropoietin for autologus transfusion in a patient with
alloimmunization, systemic lupus erythematosis, anemia and renal fail-
ure. B. Page, D. Chauveau, Ph. Mauriat, S. Chauvaud, F. Audat, and
J. Cartron, Déparlement de Nephrologie, Hôpital Necker, Service de
Chirurgie Cardiaque, Hôpital Laennec, Service de Chirurgie Car-
diaque, Hôpital Broussais, Centre de Transfusion Sanguine, Hópital
Necker, Paris, France. The risk of transmission of HIV during trans-
fusion has led to increasing use of autologous transfusion. In some
cases, it is the only possible type of transfusion. A 42-year-old female
was admitted for SLE, anemia, chronic renal failure (plasma creatinine
580 jsmol/liter) and severe valve disease. Cardiac surgery was required
for mitral, aortic and tricuspid failure. Severe anemia (Hb 5.5 gIdl) was
poorly tolerated and due both to renal failure (reticulocytes 25,000/
mm3) and SLE (inflammatory syndrome and hemolysis on positive
Coombs test). Her blood group was A positive, cc Dee, Kell negative,
Fy (a+), Ss. Test for irregular agglutinins was positive: anti-Kell, C, E,
Jka alloantibodies secondary to transfusions and/or previous pregnan-
cies. Three laboratory-compatibilized transfusions were failures (chills,
fever and hypotension). Treatment with human recombinant erythro-
poietin (EPREX, Cilag, France) was administered subcutaneously at a
dose of 8,000 units per day. Iron supplementation, corticosteroid
treatment and polyvalent immunoglobulins were also prescribed. He-
moglobin rose from 5.5 to 9 g/dl, hematocrit from 17% to 29% and
reticulocytes from 25,000 to 300,000/mm3. Over 84 days, 2,770 ml of
blood was taken for preparation of six red cell units. The patient
underwent surgery in April 1990. The mitral and tricuspid valves were
repaired and a Carpentier ring inserted. The post-surgerical course was
uncomplicated. On discharge, hemoglobin was at 10 g/dl and plasma
creatinine at 240 .unoL/liter. Four red cell units were transfused during
and two after surgery. No homologous transfusion was required. In
some patients, immunization and development of multiple alloantibod-
ies is observed after transfusion. For these patients only autotransfu-
sion can be used. rHuEPO can be used to stimulate erythropoiesis and
increase red blood cells. Autotransfusion requires cooperation among
the various actors involved in transfusion: physicians, anesthestists,
surgeons and hemobiologists. Success depends on patience, motiva-
tion, cooperation and organization.
Recurrent clotting of arteriovenous fistula associated with deficiency of
coagulation inhibitor. B. Page, 5. Houhou, J. Zingraff, and P. Bourque-
lot, Département de Nephrologie, Hôpital Necker, and Service d'Urol-
ogie, Hôpital Saint Joseph, Paris, France. Deficiency of physiological
inhibitors of coagulation, protein C and protein 5, is responsible for
severe and recurrent clotting. In a small number of hemodialysis
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patients, recurrent clotting of the vascular access is a major problem,
requiring repeated surgery and angiography. We report a series of five
hemodialysis patients, three females and two males, aged 29 to 61 years
(mean 47.8), admitted for recurrent clotting of vascular access. Renal
failure was due to membranoproliferative glomerulonephritis in one
case, urological disorder in one case and undetermined in the other
three. Patients underwent a mean of 10 thrombotic episodes (range
8—21) over 11.4 years (range 1—20). Coagulation study included platelet
count, quick time, factor II, V, VII + X levels, kaolin cephalin time,
fibrinogen, antithrombin III, protein C, and total and free protein S,
circulating anticoagulant level and search for anticardiolipin antibodies.
Three patients had a deficit in protein C and two in protein S. Platelet
count, coagulation factors and antithrombine III were normal in all
patients. No circulating anticoagulant or anticardiolipin antibodies were
found in any patient. No patient was receiving erythropoietin. Antivi-
tamin K treatment was prescribed in four patients, with no recurrence
of clotting. We conclude that in hemodialysis patients having recurrent
clotting of vascular access, a deficiency of coagulation inhibitor should
be routinely sought.
Correction of anemia by subcutaneous administration of human recom-
binant erythropoietin in renal transplant recipients with chronic rejec-
tion. B. Page, Ch. Legendre, and H. Kreis, Hôpital Necker, Paris,
France. To investigate the effect of human recombinant erythropoietin
(rHuEPO) in renal transplant recipients with chronic rejection, we
treated 12 patients (Hb < 9g/dl, serum creatinine level >200 mol/liter)
with rHuEPO. The starting dose of rHuEPO was 50 U/kg, three times
per week, by subcutaneous injections. Monthly adjustments were made
to maintain hemoglobin in the range of 10 to 12 g/dl. Follow-up period
was 24 weeks. In all patients (3 women, 9 men, aged from 29 to 54
years, mean 42 8), anemia responded to rHuEPO. Mean hemoglobin
increased from 7.4 g/dl 1.2 to 10.4 1 (P < 0.00001) and hematocrit
increased from 21.8% 3.6 to 31 3.1 (P < 0.00001). The mean
maintenance dose of rFIuEPO decreased from 150 to 80 U/kg/week at
the end of the 24 week study. There were no statistically significant
changes in white blood cell, platelet counts and plasma K concentra-
tion. The mean serum creatinine concentration was 317 tmol/liter 81
at baseline and 318 84 at the end of study. During the study one
patient required the initiation of dialysis, and in three rHuEPO was
interrupted because of infectious diseases. Minor adverse effects could
be attributed directly to rHuEPO therapy: pain at injection site (2) and
hematoma (2). None developed circulating antibodies to rHuEPO.
Eleven patients were taking antihypertensive medication (mean 2
drugs). Only two patients had increase in blood pressure requiring
additional medication. In conclusion, subcutaneous rHuEPO adminis-
tered three times per week was an effective treatment of anemia in renal
transplant recipients with chronic rejection. The responses of our 12
patients to rHuEPO were similar to those of patients on dialysis. Renal
function did not alter significantly.
Twin femoral catheters: Desperate vascular access for hemodialysis. B.
Page, C. Legendre, M. Souissi, and J.F. Moreau, Service de Réani-
mation et Transplantation, and Service de Radiologie, Hôpital Necker,
Paris, France. Transient vascular access for hemodialysis is a daily
problem in nephrology. Internal jugular twin catheters, using Canaud's
technique, is the method of reference which we have applied since 1987.
In five cases where the internal jugular route was impracticable, twin
catheters via the femoral route were used (in 4 males aged 39, 49, 64 and
80 years, and in one female aged 28 years). Four were cases of chronic
renal failure and one was an acute renal failure case. The femoral route
was required due to the occurrence of hemothorax during placement ofjugular catheters in one case, to tracheotomy in two cases, and to
hematoma at the neck in two cases. The catheter was placed by
percutaneous route, at the bedside, in rigorous aseptic conditions and
with local anesthesia. The catheters emerge at mid-thigh. Mean place-
ment time was 45 minutes. The ideal site for the distal end of the
catheters is in the inferior vena cava. No traumatic complication
occurred during placement. Three cases were ambulatory outpatients.
The hemodialysis sessions were carried out with a blood flow rate
between 200 and 300 mI/mm, giving a return venous pressure between
50 and 175 mm Hg. In one case the catheters were removed due to
insufficient flow rate caused by clots at the distal end, because of
insufficient anticoagulant treatment. In two other cases the catheters
were removed after use. Two catheters are still in place with no
problem. No infectious episode was observed. All the catheters that
were removed were sterile in culture. No thrombosis of femoral, iliac or
inferior cava veins was observed by echodoppler after removal of the
catheters. In conclusion, twin femoral catheters are a good alternative
when jugular access is impossible or contraindicated. This means of
temporary vascular access is currently under evaluation.
Femoral arteriovenous fistula after vascular puncture for hemodialysis.
B. Page, M.P. Morin, E.L. Rody, M. Souissi, M. Lacombe, and J.J.
Moreau, Département de Nephrologie and Service de Radiologie
Urinaire, Hôpital Necker, Paris, France. From 1978 to 1991 we
observed 10 patients who developed femoral arteriovenous fistula after
venous puncture for hemodialysis. The fistula most often appeared after
several punctures, but three developed after a single puncture. Diag-
nosis was made on the basis of local observation and auscultation of the
vessel (bruit + thrillN = 10, hematoma N = 4, pulsatil mass N = 1).
Two patients had arteriography and two had echodoppler. Arteriogra-
phy was not required for diagnosis (since clinical signs were sufficient),
or for treatment, since echodoppler and surgery indicated the location
of the fistula. Five patients underwent surgery. In all cases, continuity
of the main vessels of the lower member was maintained or reestab-
lished during surgery. Surgery is mandatory for high flow rate. Such
fistulas cannot be used for hemodialysis and can cause cardiac failure in
a patient with another fistula. Surgery should not be undertaken too
early because of the possibility of spontaneous clotting (particularly if
echodoppler shows low flow rate), and to allow organization of the
lesions and easier dissection. Auscultation of the vessel should be a
routine procedure after any femoral vein puncture in order that this
complication not be overlooked.
Malignant pheochromocytoma: Study of three cases. B. Page, M.P.
Morin, and M. Lacombe, Département de Nephrologie, Hôpital
Necker, and Consultation de Chirurgie, Hôpital Beaujon, Paris,
France. We report three observations of malignant pheochromocytoma
in one female and two males, respectively 27, 30 and 49 years of age at
the time of diagnosis. In all cases, the presenting symptom of pheo-
chromocytoma was permanent hypertension associated with hyperten-
sive crises. Malignancy was confirmed by metastases in organs where
no embryologic residue is normally present: lymph node, liver, lung and
brain. In two cases metastases appeared 11 and 12 years after apparent
cure of a histologically benign pheochromocytoma. Both patients died
of the disease after courses of 16 and 18 years, respectively. One is
presently considered cured after four operations to remove eight
metastases, with a follow-up of 24 years. Conclusions: (1) After excision
of an apparently benign pheochromocytoma, careful monitoring should
be continued and should include regular assessment of catecholamines
for at least 15 years. Malignancy is confirmed only by the presence of
metastases. The spontaneous course is relatively slow. (2) Renewed
increase in catecholamine level suggests malignant pheochromocy-
toma, and metastases or local recurrence should be sought. (3) Malig-
nant pheochromocytoma should be treated by aggressive surgery. The
use of modern imaging and preoperative medical preparation has led to
improved results of such surgery when performed by experienced
teams.
Infection of hemodialysis vascular access after percutaneous endolumi-
nal angloplasty and insertion of an intravascular stent. B. Page, M.P.
Morin, B. Lebkiri, L. Boudier, H. Izou, A. Raynaud, and R. Maillet,
Service de Reanimation, Hôpital Necker, Paris; Clinique de l'Alma,
Paris; Clinique Labrouste, Paris; Clinique Armand Brillard, Nogent,
France. Infection of the vascular access in a hemodialysis patient after
endoluminal angioplasty is rarely observed. We report two cases. Case
N° 1: Mr. D., 48 years of age and treated by hemodialysis for 15 years,
was hospitalized for fever and chills which appeared 48 hours after
percutaneous endoluminal angioplasty of the radial arteriovenous fis-
tula. Eight blood cultures were positive for pseudomona aeruginosa.
Despite appropriate antibiotic treatment with imipeneme and amikacin,
septic shock occurred. The fistula was ligatured and closed. Preopera-
tory sampling (thrombi) showed the same germ. The evolution was
subsequently favorable. Case N° 2: Mrs. T., 50 years of age and treated
by hemodialysis for three years for polycystic disease, presented fever
and chills 48 hours after percutaneous endoluminal angioplasty of a left
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humeroaxillary PTFE and placement of two Med Invent 150 x 8 mm
and 50 x 8 mm intravascular stents. Four blood cultures were positive
for staphylococcus aureus. The fistula was ligatured and the two stents
removed surgically. Antibiotic treatment associated vancomycin, ox-
acillin and netilmycine. Subsequent evolution was favorable. Vascular
access infection is life-threatening to hemodialysis patients. A nosoco-
mal origin is suggested by their occurrence after percutaneous endolu-
minal angioplasty and placement of stent. In both observations cure
necessitated sacrifice of the infected vascular access.
Severe respiratory syncytial virus pneumonia in an adult renal trans-
plant recipient. B. Page, P. Rieu, M.P. Morin, N. Chkoff, E. Thervet,
C. Legendre, and H. Kreis, Service de Transplantation Rénale, Hôpital
Necker, Paris, France. Respiratory syncytial virus (RSV) is the major
cause of acute lower respiratory illness in infants and young children,
and is rare in adults. RSV pneumonia may be a severe disease in
immunocompromised patients. Only sporadic cases have been docu-
mented in renal transplant recipients. We report a case of severe RSV
pneumonia in a 54 year old female renal transplant recipient. Renal
transplantation was performed in September 1983. She was receiving
maintenance immunosuppressive therapy with prednisone, azathio-
prine and cyclosporine. She was admitted in January 1992 for fever
(39°C), dyspnea and sinusitis. Bilateral alveolo-interstitial pneumonia
was confirmed by chest x-ray. Major hypoxemia was present (partial
pressure of oxygen was 40 mm Hg room air). Respiratory rate was 30
breaths per minute. Syncytial virus was isolated by direct immunoflu-
orescence in bronchoalveolar lavage fluid. Other investigations (com-
mon bacteria, mycobacteria, pneumocystis carinii, nocardia, cytomeg-
alovirus, herpes simplex, adenovirus, parainfluenza and influenza virus,
legionella) were all negative. Treatment with aerosotized ribarivin
(VIRAZOLE, ICN Pharmaceuticals, California, USA) was started and
continued for six days at the dose of 6 g of aerosolized drug over 20
hours a day. Intravenous Pefloxacine 800 mg/day, and oxygen supple-
mentation by facial mask were associated. Azathioprine and cyclospo-
rine were discontinued for four days. Isolation precautions according to
CDC Atlanta recommendations were taken. The patient became afe-
brile. After 10 days, arterial blood gas values and chest x-ray were
normal. No adverse effects of ribavirin were observed. She continues to
do well with good allograft function. In this case, the infection may have
been of familial origin because it occurred at the peak of the annual
outbreak of RSV in the pediatric units of our hospital, and one child in
the patient's family was ill with fever, cough and bronchiolitis. Efficacy
of ribarivin aerosol therapy is confirmed in our patient. Isolation
precautions were important because of the possibility of nosoconial
transmission of RSV. In conclusion: (I) RSV pneumonia must be
considered in the differential diagnosis of fever and pulmonary infil-
trates in renal transplant recipients. (2) Detection of RSV antigens by
rapid methods must be systematically performed on bronchoalveolar
lavage. (3) Specific treatment can be successfully administered.
Receptors for atrial natriuretic peptide are decreased in the kidney of
rats with streptozotocin-induced diabetes mellitus. Leonardo A. Sechi,
Jean-Pierre Valentin, Michael H. Humphreys, and Morris Schambe-
Ian, Divisions of Endocrinology and Nephrology, San Francisco Gen-
eral Hospital, University of California San Francisco, San Francisco,
California, USA. Both the renal hemodynamic and natriuretic re-
sponses to atrial natriuretic peptide (ANP) are blunted in diabetes
mellitus. To determine whether this decrease in responsiveness is
mediated by alterations in the renal ANP receptor, ANP receptor
density and affinity were measured in Sprague-Dawley rats 17 to 20
days following the administration of streptozotocin (STZ), and com-
pared to values in vehicle-treated controls and STZ-treated rats made
euglycemic with insulin. Receptors were measured using a ['251]-rat
ANP128 in situ receptor binding assay performed on frozen tissue
sections. Nonspecific binding was determined in the presence of
unlabeled rat ANP (1 /.M). Clearance receptors (ANPR-C) were iden-
tified by competition with 10 LM C-ANP4-23. Plasma ANP concentra-
tion was significantly greater in hyperglycemic diabetic rats (329 41
pg/mI) than in control (229 20, P < 0.05) or euglycemic diabetic rats
(178 22, P < 0.025). ANP receptor affinity, expressed as the apparent
dissociation constant (Kd), did not differ among the three study groups,
whereas the maximum binding capacity (Bm,j for ANP receptors was
decreased significantly in hyperglycemic diabetics (15.5 2.5 pmol/
mm3 of tissue) in comparison to controls (27.1 3.2, P < 0.01) and
euglycemic diabetics (23.9 4.6, P < 0.01). Clearance receptors were
also decreased significantly in hyperglycemic diabetic rats (0.18 0.05
pmol/mm3 of tissue) in comparison to controls (0.37 0.05, P < 0.05)
and euglycemic diabetic (0.28 0.04, P < 0.05) rats. To determine
whether the decreased number of renal ANP receptors in diabetic rats
was associated with a decreased biological response, rats were isolated
and incubated in vitro with increasing concentrations of ANP, and
cyclic GMP (cGMP) production was measured in the supernatant
following trichloracetic acid precipitation. cGMP production, measured
as the area under the dose-response curves, was significantly less in
hyperglycemic diabetic rats (802 59 fmol/mg prot/lO mm) than in
controls (1,026 67, P < 0.05) and in euglycemic diabetic rats (969
55, P < 0.05), and this difference persisted when phosphodiesterase
activity was inhibited by 3-isobutyl-1-methylxanthine or zaprinast.
Thus, the decreased number of biologically active ANP receptors in the
kidneys of diabetic rats provides a potential explanation for the reduc-
tion in renal sensitivity to the hormone.
High incidence of neurologic complications following rapid correction
of severe hyponatremia in psychogenic water drinkers. R.S. Tanneau, B.
Bourbigot, F. Rouhart, Ph. Richard, T. BenSoussan, M. Garré, Unite
de Transplantation, Service de Reanimation Medicale, Service de
Neurologie, CHU Brest, Brest, France. In self-induced water intoxica-
tion (SIWI) rapid correction of plasma sodium concentration (PNa) to
near normal levels is usually safe, probably due to acute development of
hyponatremia. However, it may be harmful in some patients. We
reviewed retrospectively the neurologic outcome in 24 episodes of
SIWI (PNa: 109 4 mmol!liter, 99—115) occurring in 12 patients over a
10 year period. One patient had 12 episodes related to hiccups-induced
potomania. He recovered uneventfully after PNa had increased by a
mean of 23 5 mmol/liter over the first 48 hours (bPNa48) with a
maximal rate of correction over a 24 hour period (R24max) of 0.64 0.17
mmol/liter/hr. Eleven patients had psychosis (N = 9) or depression. A
delayed neurologic deterioration occurred in five of them, in one case
after delayed therapy and in the other four after undelayed, prompt
correction (R24mx 0.96 0.16 mmol/liter/hr, bPNa48 27 5 mmol/liter)
by water restriction alone (N = 1) or combined with hypertonic saline.
Three out of these four patients had quadriparesis with pseudobulbar
palsy and the fourth became unresponsive to verbal stimuli. Concom-
itant PNa was above 145 mmol/liter (146—148) in two cases and  135 in
the other two (in one case the neurologic status worsened again leading
to death, following an additional increase to 146 mmol/liter). These four
patients were chronic alcoholics and in two of them SIWI developed
subacutely. The other patients recovered uneventfully despite a maxi-
mal correction rate of 1.6 0.8 mmol/liter/hr over 6 3 hr with R24max
0.67 0.24, PNa48 20 6 rnmol/liter. However, as in the first patient
none of them had underlying chronic alcoholism and the highest PNa
was 145 mmol/liter. Thus, along with the responsibility of overcor-
rection in the occurrence and/or the severity of delayed brain damage
we point out the detrimental role of alcoholism and subacute develop-
ment of hyponatremia. Whenever subacute SIWI and chronic alcohol-
ism cannot be ruled out as is often the case in outpatients, a high rate of
correction should be maintained only during the first few hours,
followed by late normalization of PNa. A guideline for controlling
correction kinetics in SIWI is given.
Nodular glomerulosclerosis with y4 heavy chain (H) and no light chain
(L) deposits. G. Touchard, M. Bauwens, J.M. Goujon, P. Siohan, P.
Aucouturier, J.L. Preud'Homme, and D. Patte, CHU Poitiers, France.
A 59-year-old Caucasian woman presented in July 1991 with nephrotic
syndrome, hypertension and chronic renal failure. Past history was
marked by hypertension, obesity, type II diabetes, Hashimoto's disease
and auto-immune thrombopenia. Urinary protein output was 6.5 g/day
and platelet count was 30,000/mm3. Ig (30 g/day) were given i.v. during
five days; platelet count rose from 30,000 to 220,000/mm3 and creat-
ininemia from 140 to 630/imol/liter. Three renal biopsies were per-
formed in July '91, September '91 and October '92. They showed
nodular glomerulosclerosis with diffuse mesangial, capillary glomeru-
lar, capsular and tubular basement membrane and parietal vascular
deposits. These deposits stained with antibodies to y chains, the y 4
subclass (using an anti-y 4 CH3 antibody) and to the y CH2 domain.
They were unreactive with polyclonal and/or monoclonal antibodies to
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the y CH1 domain, to the yl, 72 and y3 isotypes and to ic and A L
chains. Electron microscopy revealed osmiophilic granular deposits
typical of Randall's disease. Serum and urine immunoclectrophoresis
analysis showed a monoclonal IgG2 A without BJ A. Serum immuno-
blotting disclosed multiple monoclonal 1g. the prominent ones being
IgG2 A and IgG3 K, but IgG4 was diffuse. Study of bone marrow and
thyroid B cells failed to disclosed any monoclonal y4 proliferation. The
present data suggest the deposition of H chains (without L chains)
possibly lacking the CH1 domain (as in H chain diseases (HCD), in a
patient with autoimmune abnormalities (as frequently observed in
HCD). Although the absence of detectable plasmacytic proliferation (as
in several HCD cases) precluded precise characterization of the depos-
ited H chains, we propose the denomination of HCDD (for heavy chain
deposition disease) for the present condition.
Role of atrial natriuretic peptide (ANP) in the natriuretic action of
gamma-melanocyte stimulating hormone (y-MSH). J.P. Valentin, X. W.
Chen, W.Z. Ying, E. Wiedernann, and M.H. Humphreys, Divisions of
Nephrology and Endocrinology, San Francisco General Hospital;
University of California San Francisco, San Francisco, California,
USA. y-MSH is implicated as an endocrine mediator of natriuresis in
response to cardiovascular reflex stimuli. Intravenous infusion of
synthetic 72-MSH (200 pmol/min) for 120 minutes to anesthetized rats
increased plasma immunoreactive (ir) y-MSH concentration eightfold
over vehicle-infused animals and led to a progressive increase in sodium
excretion (UNaV) from 830 153 to 4306 552 nEq/min (P < 0.001).
The plasma concentration of ir-ANP increased threefold at the end of
the infusion (P < 0.001) and a correlation between the concentration of
the two peptides existed (r = 0.49, P C 0.05). Urinary excretion of
cyclic OMP (UcGMPY) rose in parallel with the increase in UNaV;
both ir-y-MSH and ir-ANP concentrations at the end of the infusion
correlated with the increase in UcGMPV (r = 0.69 and r = 0.46,
respectively). In the presence of anti-ANP antiserum, the natriuretic
action of y.MSH was reduced by one-third. y-MSH infused into a renal
artery (0.5—3 pmol/min) led to an ipsitateral increase in UNaV from 375
22 to 1341 198 nEq/min (P C 0.001) without change from the
controtateral kidney. This natriuresis was accompanied by a small
increase in UcGMPV that did not correlate with the increase in UNaV
and was abolished by prior renal denervation. Thus, y-MSH can
increase UNaV in association with increased ir-ANP and UcOMPY. It
can also cause natriuresis through a direct, intrarenal mechanism
requiring intact renal nerves, Each of these consequences of the peptide
could contribute to its role as a possible regulator of sodium balance.
Cellular basis for blunted volume expansion natriuresis in rats with
Heymann nephritis. Jean-Pierre Valentin, Wei-Zong Ying, Changbin
Qiu, Leonardo A. Sechi, and Michael H. Humphreys, Divisions of
Nephrology and Endocrinology, San Francisco General Hospital,
University of California San Francisco, San Francisco, California,
USA. Rats with experimental nephrotie syndrome resulting from adri-
amycin treatment have renal resistance to infused atrial natriuretic
peptide (ANP). To determine if resistance to the renal actions of ANP
also occurs in an immunologically mediated model of nephrotic syn-
drome, we examined renal sodium handling in rats with Heymann
nephritis (HEN). Rats were studied 10 to 14 days following i.p. injection
of anti-Fx1A antiserum. HEN had a blunted volume expansion natri-
uresis (YE: 2% body weight isotonic saline infused over 5 mm),
excreting sodium at only half the rate of normat controls (CTL) despite
similar increase in plasma atrial natriuretic peptide (ANP) concentra-
tion. Urinary excretion of cyclic GMP was also reduced by half in HEN
compared to CTL. We next compared cGMP accumulation by isolated
glomeruli and inner medullary collecting duct (IMCD) cells in response
to increasing concentration of ANP, urodilatin (URO), and sodium
nitroprusside (NPX). Results (fmol/mg prot/tO mm) are means sEat:
Glomeruli IMC
CTL
D cells
HENCTL HEN
ANP, l0 M 806 76 548 7T 522 65 231 43
URO, i0 at 895 152 383 2& 431 54 242 46
NPX, 105at 521±65 344± 314±66 171±20
a Significantly less than CTL, P C 0.05.
Basal accumulation of eGMP was not different among the groups. HEN
rats had reduced cGMP accumulation in response to ANP, URO, and
NPX. In binding studies using '251-ANP, no difference in either density
or affinity was found between CTL and HEN rats. However, when
glomeruli were incubated with ANP or NPX in the presence of
phosphodiesterase inhibitors (IBMX or M&B22,948, each at to-i at),
no difference in cGMP accumulation between CTL and HEN occurred.
Infusion of M&B22,948 into one renal artery of HEN rats normalized
the natriuretic response to YE from the infused but not the contralateral
kidney. Thus, there is a renal resistance to ANP in rats with HEN, that
can be extended to other agents acting through the cGMP pathway.
This resistance is not due to impaired binding of ANP, but to impaired
accumulation of cGMP in responsive tissues, reflecting increased
cGMP catabolism by phosphodiesterase.
Calcium carbonate crystals promote epitaxial calcium oxalate crystal
growth. J.M. Verdier, B. Dussol, S. Nitsche, P. Bert hezéne, P. Dupuy,
R. Boistelle, Y. Berland, and J.C. Dagorn, INSERM U315, Marseille;
Hdpital Sainte-Marguerite, and CRMC, Marseille, France. Calcium
oxalate (OxCa) urolithiasis is the most common urinary stone disease in
the occident. Its pathophysiology is not well-understood. Recent data
show that fluid in the thin segment of Henle's loop is supersaturated
with respect to calcite and brushite. We have demonstrated the pres-
ence of a renal protein related to pancreatic lithostathine, the pancreatic
inhibitor of calcium carbonate (CaCO3) crystal growth. This protein,
that we called renal lithostathine, is also an inhibitor of CaCO3 crystal
growth in vitro. Taken together, these data prompted us to look for the
nucleation of OxCa crystals onto CaCO3 seeds. Seeds of vaterite or
calcite were added to a metastable solution of sodium oxalate and
calcium chloride containing traces of 45Ca. The accretion of OxCa was
monitored by 45Ca-radioactivity incorporation. We showed that: (i)
seeds of vaterite and calcite may initiate nucleation of OxCa, this
nucleation being greater with vaterite than with calcite; (ii) the incor-
poration is closely related to the amount of seeds added. Moreover,
using scanning electron microscopy, we clearly demonstrated epitaxial
nucleation of OxCa crystals onto calcite and probably heterogeneous
nucleation onto vaterite. These results show that calcite may act as
heterogenous nucleus for calcium crystals. As a consequence renal
lithostathine, an inhibitor of CaCO3 crystal growth could secondarily
prevent OxCa stone formation.
